Search results
Showing 91 to 105 of 661 results for diabetes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who received individual care processes in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who received individual care processes in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have had their urinary albumin recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who have had their smoking status recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have had their smoking status recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have had their urinary albumin recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (HTG371)
Evidence-based recommendations on implantation of a duodenal-jejunal bypass liner for managing type 2 diabetes. This involves attaching a liner as a barrier between food and the upper part of the bowel, with the aim of lowering blood sugar levels.
Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]
Topic prioritisation
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1006)
NICE is unable to make a recommendation about the use in the NHS of empagliflozin (Jardiance) for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim did not provide an evidence submission.
Show all sections
Sections for TA1006
In development Reference number: GID-TA11644 Expected publication date: 22 October 2026
Peripheral arterial disease: diagnosis and management (CG147)
This guideline covers diagnosing and managing peripheral arterial disease (PAD) in people aged 18 and over. Rapid changes in diagnostic methods, endovascular treatments and vascular services associated with new specialties in surgery and interventional radiology have resulted in considerable uncertainty and variation in practice. This guideline aims to resolve that uncertainty and variation.
This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM13
pulmonary embolism - Diabetes Guideline Updates planned and in progress Diabetes in pregnancy: management from preconception